Ron Downey - FSD Pharma Co-Founder, Chairman and CEO
| HUGE Stock | USD 0.46 0.04 8.00% |
Chairman
Mr. Ron Downey is Chief Executive Officer, Director of the Company. Mr. Downey is the cofounder and CEO of Massive Interactive. Prior to forming Massive in Sydney, Australia in 1996, he was the General Manager at Terabyte Interactive, Auckland, New Zealand . Before moving into digital technology, Mr. Downey worked in the advertising and music industries as a writer, composer, artist and producer since 2014.
| Age | 53 |
| Tenure | 10 years |
| Address | 199 Bay Street, Toronto, ON, Canada, M5L 1A9 |
| Phone | 416 854 8884 |
| Web | https://www.fsdpharma.com |
FSD Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4302) % which means that it has lost $0.4302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8391) %, meaning that it created substantial loss on money invested by shareholders. FSD Pharma's management efficiency ratios could be used to measure how well FSD Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -1.62. The current year's Return On Capital Employed is expected to grow to -1.47. At present, FSD Pharma's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 11.1 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.8 M.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| KarlLudwig Kley | MERCK Kommanditgesellschaft auf | 64 | |
| Stefan Oschmann | MERCK Kommanditgesellschaft auf | 60 | |
Management Performance
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.43 |
FSD Pharma Class Leadership Team
Elected by the shareholders, the FSD Pharma's board of directors comprises two types of representatives: FSD Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FSD. The board's role is to monitor FSD Pharma's management team and ensure that shareholders' interests are well served. FSD Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FSD Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Urban, Director | ||
| Antaine Furlong, CFO and Director | ||
| Kevin Cassidy, Vice QualityLucid | ||
| Rupert Haynes, CEO | ||
| Donal CPA, Chief Officer | ||
| Maryann Adesso, Corporate Secretary | ||
| Donal Carroll, Interim CFO, Director | ||
| Nathan CPA, Chief Officer | ||
| Andrzej MD, Vice Lucid | ||
| Anthony Durkacz, Co-Chairman of the Board | ||
| Gerald Goldberg, Director | ||
| Vladimir Klacar, Director | ||
| Lakshmi Kotra, Chief Inc | ||
| Zeeshan Saeed, President Director | ||
| Dr BPHARM, CEO Director | ||
| Max Ramsay, Chief Technical Officer | ||
| Derek Ellis, Co-Founder and Chief Creative Officer | ||
| Raza Bokhari, Co-Chairman of the Board | ||
| Ron Downey, Co-Founder, Chairman and CEO | ||
| Randell Mack, President BioSciences |
FSD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FSD Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | 15.17 M | ||||
| Shares Outstanding | 40.43 M | ||||
| Shares Owned By Insiders | 17.36 % | ||||
| Shares Owned By Institutions | 2.53 % | ||||
| Number Of Shares Shorted | 333.37 K | ||||
| Price To Earning | (1.53) X | ||||
| Price To Book | 1.82 X | ||||
| Price To Sales | 105.03 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards FSD Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, FSD Pharma's short interest history, or implied volatility extrapolated from FSD Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in FSD Pharma Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the FSD Pharma Class information on this page should be used as a complementary analysis to other FSD Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for FSD Stock analysis
When running FSD Pharma's price analysis, check to measure FSD Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FSD Pharma is operating at the current time. Most of FSD Pharma's value examination focuses on studying past and present price action to predict the probability of FSD Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FSD Pharma's price. Additionally, you may evaluate how the addition of FSD Pharma to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is FSD Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FSD Pharma. If investors know FSD will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FSD Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Quarterly Revenue Growth (0.07) | Return On Assets (0.43) | Return On Equity (0.84) |
The market value of FSD Pharma Class is measured differently than its book value, which is the value of FSD that is recorded on the company's balance sheet. Investors also form their own opinion of FSD Pharma's value that differs from its market value or its book value, called intrinsic value, which is FSD Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FSD Pharma's market value can be influenced by many factors that don't directly affect FSD Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FSD Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if FSD Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FSD Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.